1025216-57-2
Chemical Structure
Volixibat
Synonym(s): SHP626; LUM002
- CAS No.: 1025216-57-2
- Formula:C38H51N3O12S2
- Molecular Weight:805.95
IUPAC Name: ((2R,3R,4S,5R,6R)-4-(benzyloxy)-6-(3-(3-((3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydrobenzo[b]thiepin-5-yl)phenyl)ureido)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)methyl hydrogen sulfate
InChIKey: ULVBLFBUTQMAGZ-RTNCXNSASA-N
SMILES: O=C(N[C@H]1[C@@H]([C@H]([C@@H]([C@@H](COS(=O)(O)=O)O1)O)OCC2=CC=CC=C2)O)NC3=CC=CC([C@H](C4=CC(N(C)C)=CC=C45)[C@@H](O)[C@](CC)(CCCC)CS5(=O)=O)=C3
Biological Activity: Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Volixibat | 99.76% | Volixibat (SHP626) is a highly selective, minimally absorbed, and competitive apical sodium-dependent bile acid transporter (ASBT) inhibitor. Volixibat has potential for treatment for non-alcoholic steatohepatitis (NASH). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Salic K, et al. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolicaspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice. PLoS One. 2019 Jun 24;14(6):e0218459. [Content Brief]
- [2]. Palmer M, et al. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol. 2018 Mar 16;19(1):10. [Content Brief]
Keywords
